Clinical Trial: A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC

U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT07589244) titled 'A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC' on May 08.

Brief Summary: This is an open-label phase II/III clinical trial enrolling patients with advanced HCC who have failed prior ICIs. The phase II portion consists of a part A dose-escalation stage and a part B dose-expansion stage. The phase III study will be initiated following discussions with National Medical Products Administration (NMPA) regarding the phase III protocol, based on accumulated data from phase II including safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD).

Study Start Date: May 13

Study Type: INTERVENTIONAL

Con...